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Perhaps, only in a few Scandinavian countries as Norway
or Iceland, repeatedly ranked as the two highest HDI, it
would be not much daring to try to implement such polemic
strategy to increase organ supply.
For the moment, the universal rule has to remain as
always preached and proposed by the US and other
developed countries: a strong condemnation of organ
commerce and endorsement to incentives aiming to increase
organ supply from deceased donations.
Drs EA Friedman and AL Friedman end their review
suggesting that the debate in which they endorse the strategy
of organ commerce ‘is better than doing nothing more
productive than complaining’. As well stated by Dr FL
Delmonico ‘y endorsement of payment for organs could
propel other countries to sanction an unethical and unjust
standard of immense proportionsy’.4 We are quite con-
vinced that before embarking in this polemic and dangerous
adventure of legitimate organ commerce, it is necessary to
recognize the fragility of our ‘strategies’ when applied into a
world where socioeconomic inequalities prevail and poverty
does not respect boundaries.
1. http:// www.bbc.co.uk/portuguese/reporterbbc/story/2006/02/060216.
2. http:// devdata.worldbank.org. World Development database, August
2005.
3. http:// hdr.undp.org/reports/global. 2005 UN Human Development Index
Report.
4. Delmonico FL. The house committee on energy and commerce assessing
initiatives to increase organ donations. Subcommittee on Oversight and
Investigations. June 13, 2003.
M Abbud-Filho1, HH Campos2, VD Garcia3 and JOM Pestana4
1Medical School, Instituto de Urologia e Nefrologia, Organ and Tissue
Transplantation Center, CINTRANS/FAMERP-HB, de Sao Paula 3826, S J Rio
Preto, SP, Brazil;
2Federal University of Ceara, Fortaleza, CE, Brazil;
3S. Casa de Porto Alegre, Porto Alegre, RS, Brazil and
4Hospital do Rim Unifesp – S. Paulo, Sa˜o Paulo, SP, Brazil
Correspondence: M Abbud-Filho, Medical School, Instituto de Urologia e
Nefrologia, Organ and Tissue Transplantation Center, CINTRANS/FAMERP-HB,
de Sao Paula 3826, S J Rio Preto, SP, Brazil. E-mail: mabbud@tera.com.br
Response to ‘Payment for donor
kidneys: Only cons’
Kidney International (2006) 70, 604. doi:10.1038/sj.ki.5001674
Abbud-Filho et al.1 present their argument that payment
for donor kidneys whether to a deceased donor’s family
or a living donor must be viewed negatively as exploitation
of vulnerable people. Terming the case for legitimizing
and regulating kidney sales ‘naı¨ve’ and ‘simplistic’, Abbud-
Filho et al. omit mention of the 17 Americans who die
each day, while waiting for as long as 10 years, with 91 851
others (as of 2 April 2006), for a deceased donor organ
transplant.
Translating accomplishments in Brazil, with a popula-
tion of 186 million, attaining an actual deceased donor
rate of 8 per million in 2005, to the United States with a
population of 296 million would yield 2368 deceased
donors, whereas in 2005, the United Network for Organ
Sharing reported that a total of 7593 deceased kidney
donors were actually utilized in the United States. From
another perspective, despite nationwide public education
campaigns and adding willingness to be an organ donor to
several state driver’s licenses, resulting in a deceased donor
rate that is three times that of Brazil, the United States
continues to experience a progressive increase in kidney
wait times with 7478 dialysis patients on a waiting list for
5 or more years as of 24 March 2006.2
Certainly, we regret the ‘consequences of poverty and
illiteracy’ that force more than 2 billion people to exist on
less that 1 dollar per day. Nevertheless, life today is more
than the dismal contest between ‘haves’ and ‘have nots’
potrayed by Abbud-Filho et al. Indeed, according to the
United Nations in February 2005, global life expectancy at
birth, increased from 46 years in 1950–1955 to 65 years in
2000–2005, and is expected to reach 75 years in 2045–2050.3
In the least developed countries, where life expectancy
today is just under 50 years, it is expected to be 66 years in
2045–2050. Rather than devoting total emotional energy to
squelching a dissenting point of view, it is in the best
interests of intellectual inquiry to encourage the presenta-
tion and examination of the purported benefits of a
regulated market to waiting recipients, potential paid
donors, and society. In at least one country where ‘official’
governmental policy sanctions the selling of kidneys from
both living and deceased donors, there is no longer a
waiting list for potential recipients.4
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To the Editor: We applaud Kidney International for the
publication of the exchange of views on payments to organ
donors. Although we appreciate Dr Delmonico’s lifetime of
efforts on behalf of transplant patients and we realize that this
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has been a contentious subject for years,1 three specific
statements of his give us concern.2
First, his statement that Congress recently rejected donor
payments is inaccurate. Congress never voted on the Frist
bill, because it was killed in committee. Moreover, Congres-
sional decisions are usually driven by interest group politics,
not ethics, economics, or good medicine. Consequently, any
action (or inaction) taken by that body fails to support the
moral superiority of any policy position.
Secondly, Dr Delmonico’s statement regarding the need
for better preventive care is a classical ‘if-then’ fallacy of logic.
If we could prevent all kidney failure, then there would be no
shortage. That is true, but we cannot prevent all kidney
failure. When the antecedent phrase is false, then any
consequent phrase can be used to produce a true statement.
Clearly, prevention of kidney failure is a laudable goal, but
what do we do about the organ shortage until we can?
Thirdly, Dr Delmonico mentions the successes realized by
the Organ Donation Collaborative; however, although
donations have increased under that program, no one
seriously expects it to resolve the organ shortage.3 Have
patients stopped dying owing to the shortage? If not, more
needs to be done. And if that ‘more’ means donor payments,
we should begin to consider them.
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To the Editor: Years ago, Philip Held (for whom I have much
personal regard) introduced me to the writings of Dr
Kaserman.1 Thus, knowing of Dr Kaserman’s genuine and
long-standing interest in this issue, it is with much respect
that I furnish this reply.
My understanding of the Frist bill is that the Organ
Donation and Recovery Improvement Act was passed by the
Senate. The House had passed similar legislation (HR 399,
the Organ Donation Improvement Act of 2003). The Organ
Donation and Recovery Improvement Act was signed into
law by President George W Bush.2
The Organ Donation and Recovery Improvement Act
encourages organ donation, permits a reimbursement for
living donors for expenses related to organ donation, and
calls for a registry to monitor the long-term health of living
donors. All good! The bill was not killed in committee as Dr
Kaserman suggests. However, up till now, Congress has not
appropriated funding for the legislation. Perhaps that is Dr
Kaserman’s misunderstanding about this enacted legislation.
Nevertheless, the point is that the enacted legislation did not
include language that would permit the overturning of the
1984 National Organ Transplant Act that prohibits the
buying and selling of organs. That omission was intentional.
An attempt to include language for financial incentives
‘notwithstanding NOTA’ was not brought forward because of
objections from Senator Judd Gregg (Republican, NH, USA)
at least, but the staffs of Senator Kennedy and Dodd were of
similar mindset (Democrats, MA and CT, USA).
As to this bipartisan Congressional perspective, my
personal discussions with some of the following Senators,
but perhaps just as importantly with the legislative staff of
Senators Frist, Kennedy, Dodd, Gregg, Durbin, and DeWine,
and with Congressmen Bilirakis and Tauzin, and by my
presentation at the Hearings of Congressman Greenwood
(which included Democratic Congressmen Dingell, Inslee,
and DeGette), are the sources of my confidence that Congress
will not adopt a regulated market for organ sales.
Further, I would ask that Dr Kaserman not overlook
opposition to his proposal from The Transplantation Society,
The American Society of Transplantation, The American
Society of Transplant Surgeons (ASTS), the National Kidney
Foundation, the United Network for Organ Sharing (UNOS),
and the World Health Organization. Notwithstanding the
writings of some prominent members of the ASTS, that
Society is on record as recently as last week, and that it is
opposed to the buying and selling of organs. These
organizations bring a powerful testimony to the debate
that will be persuasive, were that declaration necessary in
Congressional hearings. However, any further Congressional
review of this issue is clearly not contemplated at this time.
What Congress is currently attempting to resolve is the
possibility of sanctioned paired live organ donation.3
As to Dr Kaserman’s admonition that we cannot prevent
all kidney failure, I am not suggesting that we can. But I am
asking him to consider the following: it would be much less
expensive for society to prevent the renal failure associated
with hypertension, atherosclerosis, obesity, and type II
diabetes than to have an expectation that we will resolve
those medical problems at the corner kidney vendor store.
That recommendation has international support.4 As to the
ethical challenge, this recommendation is made for a patient
population that is mainly uninsured and constitutes a
substantial portion of the list (and a sizeable portion of
those who do not get access to the list).
Which takes me to Dr Kaserman’s third point about the
list, and for me to inquire: does Dr Kaserman know of the
profile of the kidney patients who are dying on the list? Has
Dr Kaserman evaluated the profile of patients who have died
in the immediate post-transplant period with a functioning
transplant? These data must shape the debate as well. The
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